Objective: This study aimed to develop a prediction model for lymph node metastasis using a gene expression signature in patients with endometrioid-type endometrial cancer. Methods: Newly diagnosed endometrioid-type endometrial cancer cases in which the patients had undergone lymphadenectomy during a surgical staging procedure were identified from a national dataset (N = 330). Clinical and pathologic data were extracted from patient medical records, and gene expression datasets of their tumors were used to create a 12-gene predictive model for lymph node metastasis. We used principal components analysis on a training set (n = 110) to develop multivariate logistic models to predict low-risk patients having a probability of lymph node metastasis of less than 4%. The model with the highest prediction performance was selected for an evaluation set (n = 112), which, in turn, was validated in an independent validation set (n = 108). Results: The model applied to the evaluation set showed 100% sensitivity (90% confidence interval [CI], 74%Y100%) and 42% specificity (90% CI, 34%Y51%), which resulted in 100% negative predictive value (90% CI, 89%Y100%). In the validation set, we confirmed that the model consistently showed 100% sensitivity (90% CI, 88%Y100%), 42% specificity (90% CI, 32%Y50%), and 100% negative predictive value (90% CI, 88%Y100%). Conclusions: Our 12-gene signature model is a useful tool for the identification of patients with endometrioid-type endometrial cancer at low risk of lymph node metastasis, particularly given that it can be used to analyze histologic tissue before surgery and used to tailor surgical options.
E
ndometrial cancer is the fifth most common female cancer in the world 1 and the most common gynecological cancer in the United States. 2 The prognosis and survival of patients with endometrial cancer are largely predicted by histology and a staging procedure that includes a lymphadenectomy. 3 However, the performance of lymphadenectomy during surgery is controversial owing to risks of serious morbidity and deteriorated quality of life for some patients. 4, 5 Currently, many guidelines do not advocate routine lymphadenectomy, allowing for its omission in low-risk patients, especially in those with apparently early-stage endometrial cancer. 6, 7 To identify low-risk patients, many proposed models assess the risk of lymph node metastasis using well-known clinical risk factors, such as depth of invasion, tumor grade, or tumor size.
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Advances in molecular profiling have provided important insights into the biologic nature of the tumor. These advances allow researchers to study the possible use of gene expression signatures as predictive tools for clinical outcomes, including metastasis. 11, 12 Therefore, we hypothesized that a gene expression signature could predict the risk of lymph node metastasis in endometrial cancer and be used to tailor surgery. To test the hypothesis, we developed a risk prediction model using gene expression profiling and validated its reliability.
MATERIALS AND METHODS

Subsequent to gaining approvals from the scientific review board of H. Lee Moffitt Cancer Center and Research
Institute and the institutional review board of the University of South Florida, we identified cases from the Total Cancer Care (TCC) consortium network dataset of newly diagnosed endometrioid-type endometrial cancer in which the patients had undergone lymphadenectomy during a surgical staging procedure. The TCC comprises tumor specimens and clinical data from consenting patients at Florida hospitals (including H. Lee Moffitt Cancer Center) and 8 other national sites. 13 Since the TCC protocol was initiated in 2006, tissue samples have been collected and kept in frozen sections before undergoing RNA and DNA extraction, following the rigorous quality assurance and quality control procedures that are described in the TCC protocol. Some of specimens in the TCC dataset were collected before 2006 under another protocol; these specimens were handled in the same manner as described in the TCC protocol (Supplementary Table 1 , http://links.lww.com/IGC/A573).
Patients with a histologic type other than endometrioidtype endometrial cancer were excluded from this study. Clinical and pathologic data were extracted from patient medical records. Of the 562 patients in the TCC cohort, 330 fulfilled eligibility criteria for this study, with patient and tumor characteristics summarized in Table 1 . Tumors from patients under the TCC protocol were arrayed on Affymetrix HuRSTAY2z520709 GeneChips (Affymetrix, Santa Clara, Calif ), which contain approximately 60,000 probesets representing approximately 25,037 unique genes (Affymetrix HuRSTA-2a520709, Gene Expression Omnibus database: https://www.ncbi.nlm.nih. gov/geo/query/acc.cgi?acc=GPL10379). 
Statistical Analyses
To develop and validate a biomarker signature that provides a consistent prediction for stratifying the nodal status of patients in the heterogeneous population of endometrial cancer patients, we divided our patient data into 3 unique sets to be used for biomarker discovery, modeling/evaluation, and independent validation.
14 Specifically, the patients were evenly split into the 3 sets according to the dates on which they underwent surgery. This strategy was designed to ensure that the final model, having been consistently validated from the 3 sets, would be relatively independent of the potentially different clinical settings involved. The first set was used as the training set, the second as the evaluation set, and the third as the validation set.
To effectively identify genes with P values of less than 0.0001 under the null assumption, we used a 2-sample t test to compare probesets that were differentially expressed between lymph nodeYpositive and lymph nodeYnegative patients in the training and evaluation sets. Probesets with P values less than 0.01 were preselected on both sets. We adopted this statistical strategy with 2 independent patient sets for gene discovery and multivariable prediction model training to avoid the pitfalls that could arise from making multiple comparisons of a large number of candidate genes and models.
To obtain more biologically relevant gene predictors, we eliminated all nonannotated probes and selected probes from among those differentially expressed probesets that matched to genes showing copy number alterations or mutations of more than 5% in The Cancer Genome Atlas (TCGA) data. In particular, we used the cBioPortal tool for Cancer Genomics (http://cbioportal.org/) on the Uterine Corpus Endometrial Carcinoma provisional dataset generated by the TCGA Research Network (http://cancergenome.nih.gov/). After eliminating the probesets that were less biologically relevant, we generated models using multivariable logistic regression and principal components analysis (Fig. 1) ; principal component analysis was used to reduce data dimension, with the principal components explaining more than 60% of the variation in the training set. We ranked the probesets by their P values and considered the top 10 in the multivariable logistic regression models to stratify the lymph node status of patients in the training set. We then evaluated these competing models by performing fivefold cross validation, using logistic regression with lymph nodeYpositive as the outcome. Accuracy, sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV), and Youden index were calculated. On the basis of the literature, a falsenegative rate of 4% was clinically determined to be the cutoff point. 15, 16 The optimal number of probesets was then determined by comparing multiple models of varying numbers of selected probesets based on their consistent statistical significance in both the training and evaluation sets, ie, by their mean P values. We then independently validated an objective model performance with the validation set, which was completely set aside from the aforementioned training and modeling steps, for its accuracy, sensitivity, specificity, PPV, and NPV.
RESULTS
Datasets from the 330 patients with histologically proven endometrioid endometrial carcinoma were split into 3 sets in chronological order. One hundred ten, 112, and 108 patients were assigned to a training set, an evaluation set, and a validation set, respectively. The median age of patients was 63 years (range, 29Y90 years). The median number of retrieved lymph nodes was 28 (range, 1Y38), and paraaortic lymph node dissection was performed in 118 of 330 patients (35.8%). Lymph node metastasis was found in 45 of 330 patients (13.6%). The additional clinical characteristics, including clinical risk factors for lymph node metastasis, are summarized in Table 1 , and the model development process is illustrated by the flowchart in Figure 2 .
Using both the training and evaluation datasets, we developed a 12-gene signature predicting lymph node metastasis. Those genes were GREM2, FMO2, TMEM212, ESR1, RPTN, PRR9, TCHHL1, CPB1, CLCN2, ITLN2, PKHD1L1, and SLC9C2. Almost all the genes had higher mean expression in the group without lymph node metastasis than the group with lymph node metastasis, except for the CLCN2 gene, which showed lower mean expression. The probe information and corresponding genes are summarized in Table 2 . Those genes that were differentially expressed between the lymph nodeY positive and lymph nodeYnegative groups, but did not show frequent genetic alteration in TCGA's uterine endometrial cancer database, were discarded. After generating multiple prediction models using multivariate logistic regression and principal components analysis, we selected the model with the highest predictive performance by comparing Youden index values. Finally, the model with 18 probes corresponding to 12 genes was selected because of a high Youden index in the training and evaluation sets and subjected to further validation.
When we allowed the pre-determined false negative rate of 4% for lymph node metastasis, the current model showed sensitivity of 100% (90% confidence interval [CI], 74%Y100%) and specificity of 41% (90% CI, 34%Y50%) in the validation set. The NPV was 100% (90% CI, 89%Y100%), whereas the PPV was 21%. The sensitivity, specificity, and positive and NPVs for the training and evaluation sets are summarized in Table 3 . In particular, in the multivariate logistic regression analysis that included well-known clinical risk factors (deep myometrial invasion and grade 3 histology), we found the linear estimates of our 12-gene signature model to be significant risk factors, independent of other competing clinical risk factors (P = 0.005) (Supplementary Table 2 , http://links.lww.com/IGC/A573).
From the pooled analysis of 330 patients, our 12-gene signature model showed sensitivity of 100% (90% CI, 94%Y100%) and specificity of 42% (90% CI, 32%Y51%). The receiver operating characteristics curve areas were 0.77 (90% CI, 0.68Y0.87) and 0.72 (90% CI, 0.69Y0.75) for the validation set and pooled analysis, respectively. The NPV was 100% (90% CI, 98%Y100%). Among the 330 patients, 137 patients had tumors showing deep myometrial invasion, grade 3 histology, or both, indicating that they could not be classified as a low-risk group. Of the 137 patients who were not clinically determined to be low risk, our model classified 36 as low risk with no false negative, which resulted in a sensitivity of 100% (90% CI, 92%Y100%) and an NPVof 100% (90% CI, 92%Y100%).
DISCUSSION
In the current study, using a 12-gene expression signature, we developed a prediction model for identifying patients at low risk of lymph node metastasis in endometrioid-type endometrial cancer. Because the clinical usefulness of this model depends on the ability to reliably predict prognoses for patients with low risk of lymph node metastasis, we focused our analyses of sensitivity and NPVs on a low-risk group. The model showed consistently high sensitivity and NPVs in the training, evaluation, and independent validation sets. This high NPV implies that patients classified as a low-risk group by this model may forgo systemic lymphadenectomy, which may be associated with serious morbidity or deteriorated quality of life for some patients.
Notably, our 12-gene model classified one fourth of clinically high-risk patients as low-risk patients. As the model consistently showed high sensitivity and NPVs, it could provide a useful diagnostic tool for tailoring lymphadenectomy even when clinical risk factors indicate a high risk for certain patients. Although the ability to exclude certain high-risk patients from a lymphadenectomy is useful, complete clinical risk information may not be readily available at the time of surgery. A genetic signature such as ours has real-world utility in that it can be effectively performed on histologic tissue before surgery, as demonstrated by the NPV in the total data set. Despite the results from the 2 randomized trials, 4, 5 lymphadenectomy is still widely recommended when patients have clinical risk factors, such as deep myometrial invasion or high tumor grade. Thus, although more than 50% to 60% of endometrial cancer patients may be exempt from having lymphadenectomy, 40% to 50% of patients are still subject to the procedure, which may deteriorate their quality of life. If our 12-gene prediction model could identify patients without lymph node metastasis even among high-risk patients classified by clinical risk factors, it could be of great utility in the decision of whether to proceed with lymphadenectomy ( Fig. 3) . However, because our model was generated from hysterectomy specimens, it should be validated using preoperative biopsies. In addition, to fully test our prediction model as a preoperative method to individualize patients' care, it should be used in a setting where preoperative histologic type and grade, some method for determining myometrial invasion, and genetic tests are included together in preoperative biopsies. The current study has several limitations. First, although we successfully validated the 12-gene signature using chronologically independent datasets, further validation of the current 12-gene model in independent datasets from different clinical settings and centers may be necessary to fully confirm To help address this limitation, we currently plan to evaluate the performance of our model using multi-institutional patient data from the Oncology Research Information Exchange Network. Second, it is still unclear how the functional profile of the 12 genes in our model contributes to the progression of invasive phenotype of endometrial cancer. Although the functional aspect of the current model has yet to be identified, better insight may be revealed when the genetic alteration or protein expression of those genes are compared between endometrioid and papillary serous subtypes. When we reviewed the TCGA endometrial cancer dataset, we found that gene amplifications of those 12 genes were increased in the serous or papillary-serous types of endometrial cancers by comparison with the endometrioid type. Therefore, it is possible that the tumors assessed as high risk by our 12-gene expression profile may have molecular characteristics resembling serous-type endometrial cancer, although assigned as the endometrioid type by histology. Third, we did not include clinical variables such as grade or myometrial invasion to develop a prediction model, given that those variables are only attainable as postoperative data. The current study indicates that our 12-gene signature could be useful in the identification of endometrial cancer patients who have a very low risk of lymph node metastasis.
In particular, the model may help patients with high clinical risk factors to avoid unnecessary lymphadenectomy. Further validation studies will be required to determine whether the 12-gene signature model can show such clinical benefits in endometrial cancer patients.
